Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with post-treatment glioma.
Dylan Henssen, Michael Rullmann, Andreas Schildan, Stephan Striepe, Matti Schürer, Cordula Scherlach, Katja Jähne, Ruth Stassart, Osama Sabri, Clemens Seidel, Swen Hesse
{"title":"Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with post-treatment glioma.","authors":"Dylan Henssen, Michael Rullmann, Andreas Schildan, Stephan Striepe, Matti Schürer, Cordula Scherlach, Katja Jähne, Ruth Stassart, Osama Sabri, Clemens Seidel, Swen Hesse","doi":"10.3389/fnume.2026.1762984","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It remains unclear whether dynamic amino-acid (AA) positron-emission tomography (PET) has additional diagnostic value over static AA-PET to distinguish tumor progression (TP) from treatment-related abnormalities (TRA) in patients with post-treatment glioma.</p><p><strong>Methods: </strong>This was a retrospective study of patients with glioma with suspected TP who underwent dynamic AA-PET imaging. The final diagnoses were based on histopathology and/or clinical-radiological follow-up. The static PET parameters included the mean and maximum tumor-to-brain ratio (TBR<sub>max</sub> and TBR<sub>mean</sub>, respectively) and the dynamic PET parameters included time to peak (TTP) and area under the time activity curve (AUTAC). Diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUROC).</p><p><strong>Results: </strong>In total, 33 patients with adult diffuse glioma (17 females: mean age: 55.7 ± 12.2 years) were included [13 [S-methyl-<sup>11</sup>C]methionine ([<sup>11</sup>C]MET) and 20 O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine (<sup>1</sup>⁸F]FET) PET examinations]. The static parameters (TBR<sub>mean</sub> and TBR<sub>max</sub>) were significantly different between the TP and TRA groups when using [<sup>11</sup>C]MET (<i>p</i> = 0.019 and <i>p</i> = 0.013, respectively), resulting in very-good-to-excellent diagnostic accuracy (AUROC values of 0.85 and 0.93, respectively). The TBR<sub>mean</sub> values derived from [<sup>18</sup>F]FET PET data were not significantly different between the TP and TRA groups (<i>p</i> = 0.066). However, the [<sup>18</sup>F]FET PET data-derived TBR<sub>max</sub> values were significantly higher in the individuals with TP (<i>p</i> = 0.005), indicating very good diagnostic accuracy (AUROC = 0.84). The dynamic PET parameters (time to peak and area under the time activity curve) were not significantly different between the TP and TRA groups.</p><p><strong>Conclusion: </strong>This study suggests that dynamic and static AA-PET parameters have similar diagnostic capacities to distinguish TP from TRA. While static AA-PET parameters may suffice for clinical decision-making, this study did not formally assess the incremental value of using dynamic metrics in addition to static measures.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"6 ","pages":"1762984"},"PeriodicalIF":1.4000,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957138/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2026.1762984","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: It remains unclear whether dynamic amino-acid (AA) positron-emission tomography (PET) has additional diagnostic value over static AA-PET to distinguish tumor progression (TP) from treatment-related abnormalities (TRA) in patients with post-treatment glioma.
Methods: This was a retrospective study of patients with glioma with suspected TP who underwent dynamic AA-PET imaging. The final diagnoses were based on histopathology and/or clinical-radiological follow-up. The static PET parameters included the mean and maximum tumor-to-brain ratio (TBRmax and TBRmean, respectively) and the dynamic PET parameters included time to peak (TTP) and area under the time activity curve (AUTAC). Diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUROC).
Results: In total, 33 patients with adult diffuse glioma (17 females: mean age: 55.7 ± 12.2 years) were included [13 [S-methyl-11C]methionine ([11C]MET) and 20 O-(2-[18F]fluoroethyl)-L-tyrosine (1⁸F]FET) PET examinations]. The static parameters (TBRmean and TBRmax) were significantly different between the TP and TRA groups when using [11C]MET (p = 0.019 and p = 0.013, respectively), resulting in very-good-to-excellent diagnostic accuracy (AUROC values of 0.85 and 0.93, respectively). The TBRmean values derived from [18F]FET PET data were not significantly different between the TP and TRA groups (p = 0.066). However, the [18F]FET PET data-derived TBRmax values were significantly higher in the individuals with TP (p = 0.005), indicating very good diagnostic accuracy (AUROC = 0.84). The dynamic PET parameters (time to peak and area under the time activity curve) were not significantly different between the TP and TRA groups.
Conclusion: This study suggests that dynamic and static AA-PET parameters have similar diagnostic capacities to distinguish TP from TRA. While static AA-PET parameters may suffice for clinical decision-making, this study did not formally assess the incremental value of using dynamic metrics in addition to static measures.